These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9597694)

  • 1. Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone.
    Vesell ES; Korsunsky Z
    Pharmacology; 1998 May; 56(5):262-6. PubMed ID: 9597694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
    Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
    Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.
    Kharasch ED; Thummel KE; Mhyre J; Lillibridge JH
    Clin Pharmacol Ther; 1993 Jun; 53(6):643-50. PubMed ID: 8513656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
    Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
    Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
    Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
    Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotyping of cytochrome P450 2E1 in vitro and in vivo.
    Ernstgård L; Johanson G; Karlsson AS; Warholm M
    Curr Drug Metab; 2007 Jun; 8(5):493-8. PubMed ID: 17584020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of brain cytochrome P450 2E1 activity in rat with the probe of chlorzoxazone by liquid chromatography-mass spectrometry.
    Wu JY; Yue J; Feng YQ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(3-4):260-6. PubMed ID: 21196134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.
    Wang Z; Hall SD; Maya JF; Li L; Asghar A; Gorski JC
    Br J Clin Pharmacol; 2003 Jan; 55(1):77-85. PubMed ID: 12534643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.
    Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA
    Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe.
    Park JY; Kim KA; Park PW; Ha JM
    J Clin Pharmacol; 2006 Jan; 46(1):109-14. PubMed ID: 16397290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of chlorzoxazone in humans.
    Desiraju RK; Renzi NL; Nayak RK; Ng KT
    J Pharm Sci; 1983 Sep; 72(9):991-4. PubMed ID: 6631711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies.
    Yamamura Y; Koyama N; Umehara K
    Xenobiotica; 2015 Apr; 45(4):353-60. PubMed ID: 25815637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.
    Chtioui H; Semela D; Ledermann M; Zimmermann A; Dufour JF
    Liver Int; 2007 Aug; 27(6):764-71. PubMed ID: 17617119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes of CYP2E1 activity in diabetic rat model].
    Li L; Zhang Y
    Yao Xue Xue Bao; 1998 Dec; 33(12):891-5. PubMed ID: 12016852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in the disposition of chlorzoxazone.
    de Vries JD; Salphati L; Horie S; Becker CE; Hoener BA
    Biopharm Drug Dispos; 1994 Oct; 15(7):587-97. PubMed ID: 7849234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure.
    Frye RF; Adedoyin A; Mauro K; Matzke GR; Branch RA
    J Clin Pharmacol; 1998 Jan; 38(1):82-9. PubMed ID: 9597564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing.
    Witt L; Suzuki Y; Hohmann N; Mikus G; Haefeli WE; Burhenne J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():207-13. PubMed ID: 27300008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.
    Wan J; Ernstgård L; Song BJ; Shoaf SE
    J Pharm Pharmacol; 2006 Jan; 58(1):51-61. PubMed ID: 16393464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation.
    Baek HW; Bae SK; Lee MG; Sohn YT
    J Pharm Sci; 2006 Nov; 95(11):2452-62. PubMed ID: 16886191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
    Emery MG; Jubert C; Thummel KE; Kharasch ED
    J Pharmacol Exp Ther; 1999 Oct; 291(1):213-9. PubMed ID: 10490907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.